Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anastasia Ganina has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lyophilized Mesenchymal Stromal Cell-Derived Products in Regenerative Medicine: A Systematic Review of Biological Activity, Stability, Safety, and Therapeutic Effects

    by Bolat Sadykov, Abay Baigenzhin, Anastassiya Ganina, Madina Karimova, Aizhan Akhayeva, Anuar Zhunussov, Batyrbek Assembekov, Ildar Fakhradiyev

    Background/Objectives: Lyophilization may facilitate storage and distribution of mesenchymal stromal cell (MSC)-derived products. This systematic review assessed biological activity, storage stability, safety, and therapeutic effects of lyophilized MSC-derived products in regenerative medicine. Methods: PubMed, Scopus, and Web of Science Core Collection were searched through 28 August 2026. Eligible English-language original studies included in vivo animal or human therapeutic evaluations. The review was registered in PROSPERO (CRD420261426429) and reported following PRISMA 2020. Two reviewers independently selected studies, extracted data, and assessed risk of bias using SYRCLE, RoB 2, or ROBINS-I according to study design. Heterogeneity precluded meta-analysis; findings were synthesized narratively. Results: Thirty-nine studies were included from 884 records; only one contained a human interventional component. Products included conditioned medium, secretome, extracellular vesicles, and whole-cell or synthetic preparations. Sixteen studies evaluated biological activity or stability: 12 directly compared lyophilized and fresh or non-lyophilized products, whereas four assessed post-lyophilization activity without a fresh or non-lyophilized comparator. Retention depended on product formulation and processing conditions, and storage-stability evidence was limited. Twelve studies provided safety evidence; no major systemic toxicity signal emerged, although concentration-dependent cytotoxicity in vitro and transient local reactions occurred. Most studies reported improvement in at least one regenerative or functional outcome, with neutral or mixed findings in some applications. Incomplete reporting of randomization and blinding limited confidence in the evidence. Conclusions: Some lyophilized MSC-derived products retain biological properties and exhibit therapeutic activity, predominantly in preclinical models. Evidence is insufficient to establish clinical efficacy or long-term safety. Translation requires standardized manufacturing, validated potency and storage-stability testing, systematic safety assessment, and well-designed human studies.

  • Open Access

    Hepatic and Renal Responses to Mesenchymal Stromal Cell Therapy: Mechanisms and Biochemical Evidence

    by Nursulu Z. Altaeva, Baglan B. Kazhiyakhmetova, Balkiya M. Abdrakhmanova, Beksultan K. Mussin, Ardak O. Sapieva, Dinara S. Tarzhanova, Tanzira T. Yedilbayeva, Anastassiya M. Ganina, Tatyana S. Bulavinceva, Sapargul Marat, et al.

    Mesenchymal stromal cell (MSC) therapy is being investigated for hepatic and renal disorders, but biochemical changes do not necessarily establish organ regeneration or clinical benefit. This non-exhaustive narrative review evaluates direct MSC interventions and six blood analytes: alanine aminotransferase, aspartate aminotransferase, total bilirubin, total protein, urea, and creatinine. PubMed-indexed English-language studies published from 2000 through 11 October 2026 were considered when complete texts and relevant findings were accessible; reviews and methodological sources provide background. Evidence is interpreted by species, disease, specimen, cell product, comparison type, and follow-up. Proposed mechanisms include paracrine signaling, immunomodulation, and host responses to administered cells, with varying experimental support. Selected preclinical studies report biochemical improvements, whereas human findings are heterogeneous. Serum total-protein responses are limited and product-dependent, and direct serum-urea evidence is mainly preclinical. The ACT-AKI trial found no acceleration of creatinine-defined recovery, while a randomized cirrhosis follow-up showed a within-arm bilirubin decline without a significant between-group difference. Urea nitrogen, albumin, urinary protein, and filtration outcomes are distinguished from the specified concentrations. Findings are synthesized descriptively, with explicit source uncertainties. Standardized cell characterization and controlled trials combining biochemical, histological, and functional outcomes are needed to assess durable clinical benefit.

  • Open Access

    Manufacturing of Placenta- and Umbilical Cord-Derived Mesenchymal Stromal Cells: A Systematic Scoping Review of Process Parameters, Quality Attributes, and Evidence-to-Control Relationships

    by Bolat Sadykov, Abay Baigenzhin, Anastassiya Ganina, Madina Karimova, Aizhan Akhayeva, Anuar Zhunussov, Batyrbek Assembekov, Ildar Fakhradiyev

    The manufacturing of placenta- and umbilical cord-derived mesenchymal stromal cells (MSCs) varies across anatomical starting material, isolation, culture supplementation, expansion, scale-up, cryopreservation, and release testing. This variability limits comparability between products and complicates process transfer. The study aimed to map full-text evidence on manufacturing variables, process outcomes, candidate critical material attributes (CMAs), candidate critical process parameters (CPPs), critical quality attributes (CQAs), potency assays, and release strategies for human placenta- and umbilical cord-derived MSCs. A systematic scoping review was conducted using a Population–Concept–Context framework and reported according to PRISMA-ScR, with search reporting guided by PRISMA-S. Searches without publication-date restrictions were completed on 15 August 2026. Two reviewers independently screened records and full texts, and charted data were independently verified. Findings were mapped by manufacturing contrast and outcome domain; quantitative pooling was considered only when biological, process, and methodological comparability supported an interpretable common effect estimate. The primary Scopus/Web of Science search identified 18,860 records; 13,122 unique records were screened and 439 full-text reports were assessed. After 208 exclusions, 231 manufacturing reports remained; the PubMed/MEDLINE search and backward/forward citation searching contributed two and five additional unique eligible reports, respectively, after cross-source deduplication, yielding 238 included reports. The study-family sensitivity set contained 236 distinct study families after linked-report assessment. Tissue-source coding identified 183 umbilical cord/Wharton’s jelly reports, 46 placental reports, and nine multi-source perinatal reports. The most frequent domains were expansion/passaging/senescence (94/238; 39.5%), media/supplements (69; 29.0%), isolation/tissue processing (67; 28.2%), and GMP/quality/release (48; 20.2%). Direct-comparison sets included 2D versus 3D/bioreactor expansion (23 reports), explant versus enzymatic isolation (22), fresh/native versus cryopreserved material (19), HPL versus FBS (12), and hypoxia versus normoxia (10). Differences in intervention definition, tissue compartment, passage/timepoint, endpoint, and unit did not support a coherent common pooled effect. The mapped evidence supports an end-to-end development model and does not identify a universal manufacturing recipe. Anatomical starting material, isolation, culture conditions, cumulative population doublings, scale-up, cryopreservation, and potency-linked release should be treated as interdependent elements of product comparability. Formal designation of CMAs and CPPs remains product- and platform-specific and requires evidence that links process variation to relevant CQAs.

  • Open Access

    Comparative Diagnostic Performance and Clinical Effectiveness of Intraoperative Quality Control Modalities in Coronary Revascularization: a Systematic Review and Aggregate Comparative Analysis of Real-World Evidence

    by Alimzhan Yelzhassov, Almas Tolegenuly, Aidos Yerpashov, Sergey Leontyev, Assel Chinybayeva, Ayan Abdrakhmanov, Anastassiya Ganina, Adil Abdinurov

    Intraoperative graft assessment during coronary artery bypass grafting (CABG) aims to identify technical anastomotic defects before chest closure. Transit-time flow measurement (TTFM) and indocyanine green (ICG) fluorescence imaging represent complementary intraoperative assessment modalities, yet their comparative diagnostic performance against angiographic reference standards remains incompletely defined. PubMed, Scopus, Web of Science Core Collection, and CENTRAL were searched from January 2000 to February 2026 using terms for CABG, ICG, and TTFM; duplicate screening yielded κ = 0.86–0.91. Eligible studies evaluated ICG and/or TTFM against invasive coronary angiography or computed tomography coronary angiography. Methodological quality was appraised using QUADAS-2 for diagnostic cohorts and the Newcastle-Ottawa Scale (NOS) for clinical-utility cohorts. Because only three directly comparable cohorts provided sufficiently reliable paired 2×2 data, formal bivariate random-effects meta-analysis was not performed. Verified 2×2 contingency data were summarised descriptively with exact Clopper–Pearson 95% confidence intervals. Clinical-utility evidence was synthesised narratively. Eighteen unique primary clinical studies were included. Three studies (Desai et al., 2006; Yamamoto et al., 2015; Hatada et al., 2011), comprising 293 paired bypass grafts, provided directly comparable quantitative evidence. ICG demonstrated an aggregate descriptive sensitivity of 76.0% (95% CI, 54.9%–90.6%) and specificity of 99.3% (95% CI, 97.3%–99.9%). TTFM/flowmetry demonstrated aggregate sensitivity of 24.0% (95% CI, 9.4%–45.1%) and specificity of 96.3% (95% CI, 93.2%–98.2%). Formal between-modality P values were not calculated. The aggregate flowmetry estimate includes one cohort using experimental FFT-based waveform analysis (Hatada et al., 2011) and should be interpreted with caution. NOS assessment of six Tier 3 clinical-utility studies yielded scores of 5–9/9; no study provided a complete two-arm comparison with non-zero revision events in both arms, precluding pooled effect estimation. ICG fluorescence imaging showed higher descriptive sensitivity than TTFM/flowmetry for detecting structural graft abnormalities. A complementary approach combining quantitative flow assessment with selective fluorescence imaging may be considered in appropriately selected situations. Prospective multicenter studies are required before definitive recommendations can be made.

  • Open Access

    Stem Cells in Post-Stroke Regenerative Therapy: Current Role of Wharton’s Jelly Mesenchymal Stem Cells in the Orchestrum

    by Anastassiya Ganina, Naizabek Yerzhigit, Oleg Lookin, Aliya Orassay, Galiya Shaimardanova, Elmira Chuvakova, Manarbek Askarov, Abay Baigenzhin

    Background/Objectives: Modern approaches for post-stroke rehabilitation cover mechanistically different ways—from physiotherapy to digital technologies. Among these approaches, stem cell-based therapy represents probably the most complex but promising strategy. Methods: We discuss the current state-of-the-art of using mesenchymal stem cells (MSCs) in post-stroke regenerative therapy. Despite relatively wide use of bone marrow and adipose tissue MSCs, these cells represent a more mature (“adult”) state, which limits their proliferative and regenerative potentials. Compared to the “adult” MSCs, less “mature” MSCs obtained from umbilical cord, specifically Wharton’s jelly MSCs (WJ-MSCs), demonstrate unique functional capabilities and are free from certain technical and ethical issues. Results: The molecular and cellular mechanisms of action of WJ-MSCs are thoroughly discussed in comparison with abundantly used “adult” types of MSCs. We also comparatively evaluate their preclinical and clinical application for treating post-stroke patients. Recent findings indicate that not only MSCs but also their secretome/exosomes (cell-free product) represent a therapeutically beneficial cellular drug in post-stroke recovery. Specially designed and carefully evaluated protocols, which preserve the bioactivity of the cell-free product intact, are mentioned. Neuroprotective and neuroreparative properties of cell-free products—secretome and exosomes—derived from Wharton’s jelly MSCs are summarized. Conclusions: Cell-free products obtained from WJ-MSCs are an innovative adjunct therapy for post-stroke disorders, despite certain challenges and limitations of this type of therapy still present. By further investigation of the molecular composition and biological mechanisms of the WJ-MSC secretome and exosomes, their clinical applicability in neuroinflammatory and neurodegenerative pathologies will be promoted.

  • Open Access

    The Mechanistic Review of the Molecular Interface of RNA-Loaded Extracellular Vesicles: Redefining Targeted Therapy for Autoimmune Disorders

    by Aliya Orassay, Naizabek Yerzhigit, Anastassiya Ganina, Elmira Chuvakova, Oleg Lookin, Abay Baigenzhin

    Traditional treatments of autoimmune diseases relying on systemic immunosuppression often lack curative potential and have severe side effects. Mesenchymal stem cells (MSCs) are a promising alternative due to their immunomodulatory properties; however, whole-cell therapies have certain limitations. MSC-derived extracellular vesicles (EVs), including small vesicles—exosomes—have emerged as a safe cell-free therapeutic platform capable of crossing biological barriers and delivering bioactive cargo with low immunogenicity. Various types of RNAs abundantly produced by host MSCs represent a key element of EV content. In particular, EVs carry small RNAs, which essentially determine cellular life and fate. Our review provides a comprehensive mechanistic framework for the use of RNA-loaded EVs, specifically those carrying microRNAs (miRNAs), small interfering RNAs (siRNAs), and messenger RNAs (mRNAs), in restoring immune homeostasis. We detail the biogenesis and molecular mechanisms governing sorting of RNA into EVs, along with endogenous and exogenous engineering strategies to enhance therapeutic potency. We examine how RNA-loaded EVs modulate immunological processes like reprogramming of macrophage M1-M2 polarization, Th17/Treg balance, and suppression of inflammatory signaling pathways such as NF-κB and the NLRP3 inflammasome. We address critical translational challenges—EV heterogeneity, manufacturing scalability, and need for standardized quality control—while outlining future opportunities for RNA-loaded EV-based therapeutics.


  • Mesenchymal Stem Cells in Regenerative Therapy: Therapeutic Potential and Applications

    by Azamat Omargali, Tanzira Yedilbayeva, Anastasia Ganina, Aizhan Akhayeva

    The purpose of this review is to provide an updated overview of the potential use of mesenchymal stem cells (MSCs) in regenerative medicine. MSCs can be isolated from various tissues, and their biological properties largely depend on their source. Bone marrow-derived MSCs remain the most studied and widely used; however, their use is limited by the invasive nature of their collection, low cell yield, and age-related decline in regenerative potential. The human placenta offers an alternative source of MSCs for drug research and development due to its high availability, the ability to obtain large numbers of cells, and low immunogenicity. This review aims to summarize current literature data on the regenerative properties of human bone marrow and placental mesenchymal stem cells and to compare their potential for use in regenerative medicine. Keywords: mesenchymal stem cells, regenerative cell therapy, bone marrow-derived mesenchymal stem cells, placental mesenchymal stem cells.

  • Open Access

    Activated Lymphocyte-Based Immunotherapy Plus Tomotherapy in an Older Patient with Stage III Lung Cancer: A Case Report

    by Anastasia Ganina, Madina Karimova, Dana Idrissova, Aigul Brimova, Manarbek Askarov, Larissa Kozina

    Lung cancer is one of the most common malignant tumors and is associated with a high mortality rate, especially in aged patients. Immunotherapy is an effective method for treating lung cancer, particularly when used in combination with other treatments like chemotherapy. One of the types of immunotherapy is the use of autologous immune cells that are pre-activated before injection back to a patient. The effectiveness of this type of immunotherapy is determined by the specificity of its action on cancer cells through the activation of immune cell, e.g., lymphocytes. However, this treatment is not extensively used in elder patients due to higher risk of complications. On the other hand, in those aged patients who suffer from late stage cancer, the immune-cell based immunotherapy may come as a last resort. In this study, we present a clinical case of a 63-year-old patient with advanced-stage lung cancer and CT-confirmed infiltration of the left main bronchus. Treatment of the patient with immunotherapy using autologous activated lymphocytes combined with tomotherapy resulted in prominent improvement and decreased size of the malignancy. This positive effect was accompanied by a decrease in the number of circulating tumor cells in the blood. The patient was treated in May-June 2024 and is still alive with good condition as of August 2025. We conclude that combined treatment is a reliable option for selected aged patients with advanced-stage lung cancer.

  • Open Access

    Intradermal Application of Allogenic Wharton’s Jelly Mesenchymal Stem Cells for Chronic Post-Thoracotomy Wound in an Elderly Patient After Coronary Artery Bypass Grafting: Clinical Case with Brief Literature Review

    by Anastassiya Ganina, Abay Baigenzhin, Elmira Chuvakova, Naizabek Yerzhigit, Anuar Zhunussov, Aizhan Akhayeva, Larissa Kozina, Oleg Lookin, Manarbek Askarov

    Background: Chronically non-healing thoracic wounds after cardiac and non-cardiac thoracotomy, including cases when coronary artery bypass grafting (CABG) is performed, represent a great clinical challenge. It is often that a conservative treatment of the wounds does not provide effective regeneration of the damaged tissues. It is especially critical in patients with infected wounds, in patients owning a systemic infection, and in elderly people. Methods: The article presents a case report of successful treatment of a 63-year-old man with refractory chronic osteomyelitis of the sternum and mediastinitis four years after CABG, complicated by COVID-19 at the time of reconstructive surgery. Due to the low effectiveness of conservative treatment methods, a two-stage approach was applied: radical surgical wound debridement followed by infiltration of the wound with allogenic mesenchymal stromal cells (MSCs) of Wharton’s jelly (WJ-MSCs). Results: This double-stage therapy successfully modulated the inflammatory environment and stimulated granulation, facilitating final thoracoplasty and osteosynthesis. The patient achieved complete healing of the sternum, demonstrating benefits of WJ-MSCs in treating conservative treatment-resistant infections in the surgical wound. Conclusions: The advantages of using perinatal mesenchymal stem cells, with WJ-MSCs as a type of this class of MSCs, were demonstrated in treating chronically infected sternal surgical wounds. We also compared their regenerative properties to other stem cell types like bone marrow MSCs.


  • Open Access

    Extracellular vesicles and lyophilization: getting functionally stable cell-free biomedical products

    by Abay Baigenzhin, Elmira Chuvakova, Aigerim Zhakupova, Aizhan Akhayeva, Anastasia Ganina

    During the last decade, clinical application of extracellular vesicles (EVs) is of growing interest. Despite the progress in exploring the therapeutic potential of EVs, e.g. as disease markers or the carriers for therapeutic substances, it is important to identify proper storage conditions – this issue is indeed challenging. A subtype of EVs known as exosomes is of great importance in the therapeutic applications because they participate in the regulation of intercellular communication. Currently, exosomes are considered as a promising tool in the regenerative medicine. The therapeutic potential of exosomes and other subtypes of EVs, especially for their using in immunomodulation and drug delivery, dictates great attention to the methods for their storage, in particular for a long periods of time. Lyophilization is one of the best such methods designed to preserve cell-free EV-based products. In our mini-review, we discuss the main methods developed for stabilizing cell-free products and getting stable solid forms of EVs that are capable for long-term storage. We also point out that the methods need to be following both the ease of transportation and the retaining the functionally important properties for in vivo applications. The development of optimal protocols for storing the EVs are therefore crucially important for warranting that structural and functional integrity of EVs, exosomes in particular, are maintained intact or at least modified as less as possible. For comprehensiveness of our review, we refer to original studies which investigated how the storage temperature and freezing methods may affect stability of the final EV product. We summarize advances in the area of freeze-drying EVs (exosomes), the selection of optimal process parameters and lyoprotectants, the interplay between lyophilization parameters and specific functional properties of exosomes, and the preservation of their biological activity after reconstitution before application in vivo.